Our published data and the preliminary data presented in this application have demonstrated that hyperglycemia suppresses AMPK, which in turn perpetuates oxidative stress and vascular injury in diabetes. The central hypothesis of this application is that AMPK12 inhibition increases 26S activity, which increases I:B1 degradation, p65 nucleus localization, and consequent NF:B activation. Activated NF:B binds to the promoter of NAD(P)H oxidase subunits, including NOX4, gp91phox(NOX2), p67phox, p47phox, resulting in an increase in NAD(P)H oxidase activity and ROS, which causes endothelial cell dysfunction and accelerated atherosclerosis. Chronic proteasome inhibition of the 26S proteasome prevents endothelial dysfunction and atherogenesis by inhibiting proteasome-dependent NF:B-mediated activation of NAD(P)H oxidase. This hypothesis will be tested in three interrelated aims. These first two aims are designed to establish whether chronic hyperglycemia inhibition AMPK functions (Aim #1) and whether AMPK inhibition causes abnormal expression of adhesion molecules and oxidant stress in diabetes (Aim #2). Finally, we will test the contributions of RNS-mediated AMPK inhibition in the development of accelerated atherosclerosis in diabetes (Aim #3). Although the in vivo relationships among atherosclerosis, oxidant stress, and AMPK in diabetes are undoubtedly complex, the emerging role for AMPK in oxidant stress and atherosclerosis warrant further study. The studies proposed here represent the first set of definitive studies to determine the role of ONOO- and AMPK inhibition in the pathogenesis of diabetic vascular dysfunction and atherosclerosis. As such, they have the potential to explain the long recognized decrease in AMPK that occurs in animals and human patients with diabetes. We believe that the proposed studies will provide novel information as to how the metabolic stress associated with diabetes causes damage to the endothelium and how the endothelial cell attempts to protect itself against these stresses and whether ONOO- or AMPK are potential targets for therapy.

Public Health Relevance

Recent studies from the applicant's group and others support the idea that oxidant stress is a common pathogenic mechanism for cardiovascular diseases including diabetes, hypertension, and atherosclerosis. But the mechanisms are poorly defined. Thus, this application is aimed to determine 1) how diabetes inhibits AMPK in endothelial cells;2) To determine how AMPK inhibition results in excessive inflammation and oxidant stress;and 3) to determine the contribution of AMPK inhibition in diabetes-enhanced atherosclerosis in mouse models of atherosclerosis in vivo.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL074399-08
Application #
8228189
Study Section
Vascular Cell and Molecular Biology Study Section (VCMB)
Program Officer
Liu, Lijuan
Project Start
2003-07-01
Project End
2014-02-28
Budget Start
2012-03-01
Budget End
2013-02-28
Support Year
8
Fiscal Year
2012
Total Cost
$362,588
Indirect Cost
$115,088
Name
University of Oklahoma Health Sciences Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
878648294
City
Oklahoma City
State
OK
Country
United States
Zip Code
73117
Duan, Quanlu; Ni, Li; Wang, Peihua et al. (2016) Deregulation of XBP1 expression contributes to myocardial vascular endothelial growth factor-A expression and angiogenesis during cardiac hypertrophy in vivo. Aging Cell 15:625-33
Okon, Imoh S; Ding, Ye; Coughlan, Kathleen A et al. (2016) Aberrant NRP-1 expression serves as predicator of metastatic endometrial and lung cancers. Oncotarget 7:7970-8
Dai, Xiaoyan; Ding, Ye; Liu, Zhaoyu et al. (2016) Phosphorylation of CHOP (C/EBP Homologous Protein) by the AMP-Activated Protein Kinase Alpha 1 in Macrophages Promotes CHOP Degradation and Reduces Injury-Induced Neointimal Disruption In Vivo. Circ Res 119:1089-1100
Ding, Ye; Chen, Jie; Okon, Imoh Sunday et al. (2016) Absence of AMPKα2 accelerates cellular senescence via p16 induction in mouse embryonic fibroblasts. Int J Biochem Cell Biol 71:72-80
He, Chaoyong; Li, Hongliang; Viollet, Benoit et al. (2015) AMPK Suppresses Vascular Inflammation In Vivo by Inhibiting Signal Transducer and Activator of Transcription-1. Diabetes 64:4285-97
Wang, Qiongxin; Liu, Danxia; Song, Ping et al. (2015) Tryptophan-kynurenine pathway is dysregulated in inflammation, and immune activation. Front Biosci (Landmark Ed) 20:1116-43
Cai, Zhejun; Lu, Qiulun; Ding, Ye et al. (2015) Endothelial Nitric Oxide Synthase-Derived Nitric Oxide Prevents Dihydrofolate Reductase Degradation via Promoting S-Nitrosylation. Arterioscler Thromb Vasc Biol 35:2366-73
Wu, Yue; Song, Ping; Zhang, Wencheng et al. (2015) Activation of AMPKα2 in adipocytes is essential for nicotine-induced insulin resistance in vivo. Nat Med 21:373-82
Duan, Quanlu; Yang, Lei; Gong, Wei et al. (2015) MicroRNA-214 Is Upregulated in Heart Failure Patients and Suppresses XBP1-Mediated Endothelial Cells Angiogenesis. J Cell Physiol 230:1964-73
Okon, Imoh S; Zou, Ming-Hui (2015) Mitochondrial ROS and cancer drug resistance: Implications for therapy. Pharmacol Res 100:170-4

Showing the most recent 10 out of 80 publications